Association of pre- and post-chemotherapy mutation patterns with clinicopathological features.

<p>^a Mutant→Mutant, Mutant→Wildtype, Wildtype→Mutant cases</p><p>^b Fisher’s exact test, two-sided <i>P</i> value</p><p>^c Two-sample t-test, two-sided <i>P</i> value</p><p>^d One WT→WT was not evaluable for overall response</p><p>^e<i>P</i> value from analysis of CR/PR vs SD</p><p>Association of pre- and post-chemotherapy mutation patterns with clinicopathological features.</p

Study cases according to mutation status in pre- and post-chemotherapy samples and their clinicopathological and tumor response characteristics (n = 40 pairs).

<p><b>Abbreviations:</b> C1, + = tumor response ≥25% after cycle 1 chemotherapy, C1,— = tumour response <25% after cycle 1 chemotherapy; CR, complete response; ER, estrogen receptor status; Met, Presence of metastasis; MT, mutant; NE, non evaluable (patient had already started on another line of treatment); ORR, overall response rate; PgR, progesterone receptor; PR, partial response; SD, stable disease; T3, >50mm in greatest dimension; T4, tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules); WT, wildtype; -, negative/no; +, positive/yes</p><p>^a Status of respective mutation in pre-chemotherapy sample</p><p>^b Status of respective mutation in post-chemotherapy sample</p><p>^c Arm A, randomized to receive doxorubicin in first cycle; Arm B, randomized to receive docetaxel in first cycle</p><p>^d Age in years</p><p>Study cases according to mutation status in pre- and post-chemotherapy samples and their clinicopathological and tumor response characteristics (n = 40 pairs).</p

Oncogenic mutations detected pre- and post-chemotherapy.

<p>Representative chromatograms of (A) <i>PIK3CA E542K</i> in a MT→MT case HOB045, (B) <i>EGFR S768I</i> in a MT→WT case HOB035, and (C) <i>MET Y1230C</i> detected in a WT→MT case HOB090. The expected positions for the unextended primer (UEP) and the nucleotide and mutation status (mutant [MT] or wildtype [WT]) based on the size of the extension products are indicated above the gray vertical dashed lines.</p

Cumulative overall survival by ethnicity in 5,264 South East Asian women with breast cancer.

<p>Cumulative overall survival by ethnicity in 5,264 South East Asian women with breast cancer.</p

Association between Ethnicity and All-Cause Mortality Following Diagnosis with Breast Cancer in 5,264 Southeast Asian Women.

a<p>Estimated from Cox regression model adjusted for age at diagnosis, center, and year of diagnosis.</p>b<p>Estimated from Cox regression model adjusted for age at diagnosis, center, year of diagnosis, tumor size, lymph node involvement, distant metastasis, estrogen receptor status, progesterone receptor status, and tumor grade.</p>c<p>Estimated from Cox regression model adjusted for age at diagnosis, center, year of diagnosis, tumor size, lymph node involvement, distant metastasis, estrogen receptor status, progesterone receptor status, tumor grade, loco-regional therapy, chemotherapy, and hormone therapy.</p

Distribution of Patient Profile, Tumor Characteristics and Treatment According to Ethnicity in 5,264 Southeast Asian Women with Breast Cancer.

a<p>Column percentage is presented except for center where row percentage is presented.</p>b<p>Compared using χ² test for categorical variables and Kruskal Wallis test for continuous variables.</p>c<p>Absolute tumor size was only available in 4 359 patients i.e. in 80.4% of the Chinese, 89.2% of Malays and 88.5% of Indians.</p>d<p>Only includes 4,589 patients with TNM stage I to stage III breast cancer. Complete treatment consists of mastectomy, or breast conserving surgery followed by radiotherapy. Incomplete treatment includes breast conserving surgery only or radiotherapy only.</p>e<p>Only includes 2 772 patients with estrogen or progesterone receptor positive tumors.</p